![](https://endpts.com/wp-content/uploads/2024/04/Rob-Michael-AbbVie-feature.jpg)
AbbVie CEO Rob Michael
AbbVie beats expectations with smaller Humira slide — and big gains for next autoimmune blockbusters
Humira isn’t going anywhere yet. And its successors are coming along nicely, too.
On Thursday, AbbVie shared second-quarter financial results that show its cornerstone immunology …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.